McCutcheon I E, Blacklock J B, Weber R S, DeMonte F, Moser R P, Byers M, Goepfert H
Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Neurosurgery. 1996 Mar;38(3):471-9; discussion 479-80. doi: 10.1097/00006123-199603000-00009.
Transfacial approaches, traditionally used for malignant tumors of the paranasal sinuses, provide limited exposure when several sinuses are involved and are unsuitable for tumors that erode through the floor of the anterior cranial fossa. A transcranial approach may aid in the removal of such lesions. To better understand the risks and benefits of this surgical approach, we reviewed all patients (n = 76) who underwent a transcranial approach as part of the excision of paranasal sinus lesions between 1984 and 1993 at our institution. The spectrum of disease included adenocarcinoma (13 patients), squamous cell carcinoma and olfactory neuroblastoma (11 patients each), adenoid cystic carcinoma and poorly differentiated forms of carcinoma (6 patients each), melanoma (5 patients), and miscellaneous others (24 patients). Most patients had ethmoid sinus involvement; tumors were also commonly found in the cribriform plate, sphenoid sinus, and nasal fossa. In each patient, a bifrontal craniotomy was performed with extradural dissection to the floor of the anterior fossa and osteotomies for resection of involved elements. In 47 patients (62%), disease in the orbit, the anterior nasal cavity, or the soft tissues of the face required transfacial as well as transcranial resections. Bony defect in the anterior fossa floor was repaired with a pedicled pericranial flap. Patients with major complications included six patients with epipericranial and/or epidural hematomas requiring evacuation, three with transient cerebrospinal fluid leaks, two who developed bifrontal cerebral infarcts, and one who died soon after surgery. No meningitis was seen. To date, 26 patients (34%) have died; of those living (mean follow-up, 34 mo), 42 (84%) remain in full remission. The transcranial approach can achieve removal of erosive, invasive tumors from this area with predictable morbidity and may be considered whenever sinus tumors breach the anterior cranial base or extend beyond the reach of conventional transfacial approaches.
经面部入路传统上用于鼻窦恶性肿瘤,当多个鼻窦受累时,其暴露范围有限,且不适用于侵蚀前颅窝底的肿瘤。经颅入路可能有助于切除此类病变。为了更好地了解这种手术入路的风险和益处,我们回顾了1984年至1993年在我院接受经颅入路作为鼻窦病变切除一部分的所有患者(n = 76)。疾病谱包括腺癌(13例)、鳞状细胞癌和嗅神经母细胞瘤(各11例)、腺样囊性癌和低分化癌(各6例)、黑色素瘤(5例)以及其他杂类(24例)。大多数患者筛窦受累;肿瘤也常见于筛板、蝶窦和鼻腔。对每位患者均行双额开颅术,硬膜外剥离至前颅窝底,并进行截骨术以切除受累结构。47例患者(62%)眼眶、前鼻腔或面部软组织的病变需要经面部及经颅联合切除。前颅窝底的骨缺损用带蒂颅骨膜瓣修复。发生严重并发症的患者包括6例需要引流的帽状腱膜下和/或硬膜外血肿患者、3例短暂性脑脊液漏患者、2例发生双额脑梗死患者以及1例术后不久死亡患者。未发生脑膜炎。迄今为止,26例患者(34%)死亡;在存活患者中(平均随访34个月),42例(84%)仍处于完全缓解状态。经颅入路能够以可预测的发病率切除该区域的侵蚀性、浸润性肿瘤,并且只要鼻窦肿瘤突破前颅底或超出传统经面部入路的范围,就可考虑采用该入路。